Coloplast Valuation Multiples

Coloplast Overview

About Coloplast

Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

Founded

1954

HQ

Employees

17.2K

Website

coloplast.com

Sectors

Medical DevicesBioTech

Financials (LTM)

Revenue: $4B

EBITDA: $1B

EV

$21B

Valuation Multiples

Multiples.vc

Start free trial

Coloplast Financials

Coloplast reported last 12-month revenue of $4B and EBITDA of $1B.

In the same LTM period, Coloplast generated $3B in gross profit, $1B in EBITDA, and $712M in net income.

Coloplast P&L

In the most recent fiscal year, Coloplast reported revenue of $4B and EBITDA of $1B.

Coloplast expects next 12-month revenue of XXX and NTM EBITDA of XXX

Coloplast Stock Performance

Coloplast has current market cap of $17B, and enterprise value of $21B.

Coloplast's stock price is $7.63.

Coloplast Valuation Multiples

Coloplast trades at 4.8x EV/Revenue multiple, and 14.8x EV/EBITDA.

Coloplast Financial Valuation Multiples

As of March 24, 2026, Coloplast has market cap of $17B and EV of $21B.

Equity research analysts estimate Coloplast's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Coloplast has a P/E ratio of 24.1x.

Coloplast Margins & Growth Rates

Coloplast's revenue in the last 12 month grew by 6%.

Coloplast's revenue per employee in the last FY averaged $0.3M.

Coloplast's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Coloplast's rule of X is 46% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Coloplast Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Coloplast M&A Activity

Coloplast acquired XXX companies to date.

Last acquisition by Coloplast was on XXXXXXXX, XXXXX. Coloplast acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Coloplast Investment Activity

Coloplast invested in XXX companies to date.

Coloplast made its latest investment on XXXXXXXX, XXXXX. Coloplast invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).